Alterations of mast cells and TGF-&beta;1 on the silymarin treatment for CCl4-induced hepatic fibrosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

508

HTML

4601

Figures (1-6)

348

Tables (1-2)

234

Sum=5691

Feb 28, 2005 (publication date) through Jan 12, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Feb 28, 2005; 11(8): 1141-1148
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1141

Table 1 Experimental designs used in this study.

Group ID	Numberof animal	Treatment	Sacrificed time
CCl₄	15	CCl₄, 1.0 mg/(kg·d), IP 3 times a wk 0.25% CMC, 1 mL/(kg·d), PO 5 times a wk	4, 8, 12 wk
CCl₄+ Sily	15	CCl₄, 1.0 mg/(kg·d), IP 3 times a wk Silymarin, 50 mg/(kg·d), PO 5 times a wk	4, 8, 12 wk

Citation: Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ, Jeong KS. Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl₄-induced hepatic fibrosis. World J Gastroenterol 2005; 11(8): 1141-1148
URL: https://www.wjgnet.com/1007-9327/full/v11/i8/1141.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i8.1141